2-[(3S)-3-methyl-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one | 1396842-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 2-[(3S)-3-methyl-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one
• CAS: 1396842-68-4
• 化学式: C₁₆H₁₄F₃N₃O₅S
• 分子量: 417.365
• InChiKey: UZPXSNBQGRZSEV-CYQMCQFNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  122
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (S)-benzyl 2-methyl-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxylate 在 10% Pd/C 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 2-[(3S)-3-methyl-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one
  参考文献：
  名称：

  Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design

  摘要：

  1,3-Benzothiazin-4-ones (BTZs) are a novel class of TB drug candidates with potent activity against M. tuberculosis. An in silico ligand-based model based on structure-activity data from 170 BTZ compounds was used to design a new series. Compounds were tested against a panel of mycobacterial strains and were profiled for cytotoxicity, stability, and antiproliferative effects. Several of the compounds showed improved activity against MDR-TB while retaining low toxicity with higher microsomal, metabolic, and plasma stability.

  DOI：

  10.1021/jm3008882

文献信息

• Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design
  作者：Tomislav Karoli、Bernd Becker、Johannes Zuegg、Ute Möllmann、Soumya Ramu、Johnny X. Huang、Matthew A. Cooper

  DOI：10.1021/jm3008882

  日期：2012.9.13

  1,3-Benzothiazin-4-ones (BTZs) are a novel class of TB drug candidates with potent activity against M. tuberculosis. An in silico ligand-based model based on structure-activity data from 170 BTZ compounds was used to design a new series. Compounds were tested against a panel of mycobacterial strains and were profiled for cytotoxicity, stability, and antiproliferative effects. Several of the compounds showed improved activity against MDR-TB while retaining low toxicity with higher microsomal, metabolic, and plasma stability.